Want to see IN:VINEETLAB full AI Analyst Report?
VINEETLAB Stock Chart & Stats
₹40.51
₹2.19(3.77%)
At close: 4:00 PM EST
₹40.51
₹2.19(3.77%)
Day’s Range― - ―
52-Week Range₹28.00 - ₹43.56
Previous CloseN/A
Volume164.54K
Average Volume (3M)40.88K
Market Cap
₹682.78M
Enterprise Value₹788.83M
Total Cash (Recent Filing)₹170.75M
Total Debt (Recent Filing)₹453.25M
Price to Earnings (P/E)42.6
Beta0.67
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.64%
Share Statistics
EPS (TTM)0.85
Shares Outstanding19,206,266
10 Day Avg. Volume7,183
30 Day Avg. Volume40,881
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.71
Price to Sales (P/S)0.54
P/FCF Ratio-1.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Earnings RecoveryThe move from a deep 2025 loss to positive net margin, alongside stronger operating margins, shows a meaningful earnings recovery. This improves internal funding potential and demonstrates that the business can restore profitability, although the still-thin margin means durability remains to be proven.
Lower LeverageThe substantial reduction in debt-to-equity and rebuilding of equity strengthen financial resilience compared with the stressed 2025 position. Lower leverage can reduce balance-sheet pressure, preserve borrowing capacity, and give management more flexibility to support operations through future business fluctuations.
Revenue ReboundA return to revenue growth in 2026 indicates that demand and commercial activity recovered after two difficult years. If this rebound continues, greater scale could support operating leverage and reinforce the earnings recovery, though the prior volatility makes consistency an important condition.
Bears Say
Weak Cash GenerationLarge negative operating and free cash flow in 2026 indicate that reported earnings are not converting reliably into liquidity. Persistent cash deficits can increase reliance on financing, constrain investment capacity, and leave the company more exposed when demand or profitability weakens.
Volatile Revenue HistoryThe sharp multi-year swings in revenue point to an unstable top-line trajectory rather than a consistently compounding business. Such variability makes capacity planning, cost absorption, and earnings forecasting more difficult, increasing the risk that the recent recovery will not persist across cycles.
Thin ReturnsDespite the earnings rebound, very low net profitability and return on equity show that the capital base is not yet producing strong shareholder returns. Thin returns provide limited protection against cost or pricing pressure and leave less retained profit to fund growth without additional financing.
Vineet Laboratories Ltd. News
VINEETLAB FAQ
What was Vineet Laboratories Ltd.’s price range in the past 12 months?
Vineet Laboratories Ltd. lowest stock price was ₹28.00 and its highest was ₹43.56 in the past 12 months.
What is Vineet Laboratories Ltd.’s market cap?
Vineet Laboratories Ltd.’s market cap is ₹682.78M.
When is Vineet Laboratories Ltd.’s upcoming earnings report date?
Vineet Laboratories Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 13 days.
How were Vineet Laboratories Ltd.’s earnings last quarter?
Vineet Laboratories Ltd. released its earnings results on Feb 14, 2026. The company reported ₹0.923 earnings per share for the quarter.
Is Vineet Laboratories Ltd. overvalued?
According to Wall Street analysts Vineet Laboratories Ltd.’s price is currently Overvalued.
Does Vineet Laboratories Ltd. pay dividends?
Vineet Laboratories Ltd. pays a Notavailable dividend of ₹1 which represents an annual dividend yield of 1.64%. See more information on Vineet Laboratories Ltd. dividends here
What is Vineet Laboratories Ltd.’s EPS estimate?
Vineet Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vineet Laboratories Ltd. have?
Vineet Laboratories Ltd. has 19,206,266 shares outstanding.
What happened to Vineet Laboratories Ltd.’s price movement after its last earnings report?
Vineet Laboratories Ltd. reported an EPS of ₹0.923 in its last earnings report. Following the earnings report the stock price went up 2.422%.
Which hedge fund is a major shareholder of Vineet Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:VINEETLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vineet Laboratories Ltd.
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
Technical Analysis
Diamines & Chemicals Ltd.
―
DMCC Speciality Chemicals Limited
―
Indo Amines Limited
―
Primo Chemicals Limited
―
Ishan Dyes and Chemicals Limited
―